• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

AUA 2024: Dr. Weiner previews key prostate cancer research

Feature
Video

Adam B. Weiner, MD, highlights several studies in prostate cancer set to be presented at the upcoming 2024 American Urological Association Annual Meeting.

In this video, Adam B. Weiner, MD, highlights 5 studies in prostate cancer that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Weiner is a current urologic oncology fellow at the University of California, Los Angeles.

During the discussion, Weiner highlights the following presentations:

  • P2s: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)
  • P2s: Apalutamide and androgen deprivation therapy for the treatment of high-risk localized prostate cancer following radical prostatectomy in Apa-RP: a multicenter, open-label, single-arm ph
  • PD01-03: Third interim analysis (IA3) of the DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
  • PD01-06: Prostate-specific antigen dynamics from the phase 3 EMBARK trial: A post hoc analysis
  • PD39-06: A randomized clinical trial comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer. Intention to treat analysis at two-year follow-up
Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.